top of page
ANAVEX®2-73 (BLARCAMESINE)
Undisclosed Rare Disease
*
*
= Orphan Drug Designation by FDA
*
= Orange outline indicates planned clinical studies
*
ANAVEX®3-71 (AF710B)
*
Neurodegenerative Diseases
*
= Orphan Drug Designation by FDA
= Orange outline indicates planned clinical studies
ANAVEX®1-41
Neurodegenerative Diseases
ANAVEX®1066
ANAVEX 2-73
ANAVEX 3-71
ANAVEX 1-41
ANAVEX 1066
Top Menu
Our SIGMACEPTOR™ Discovery Platform consists of differentiated clinical-stage CNS assets targeting significant and growing markets. Anavex Life Sciences has patent protection to 2030-2039. World-wide rights for all listed product candidates.
bottom of page